Skip Navigation

Receive this page by email each issue: [Sign up for eTOCs]

Contents: Volume 7, Supplement 1, 1996   [Index by Author] 


Down Preface
Down Background Information
Down Acknowledgements
Down Abstracts
Down Subject Index
Down Authors Index


[Search ALL Issues]

Front Matter (PDF) | Back Matter (PDF)

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.

Preface Back

H.M. Pinedo
Preface
Ann Oncol 1996 7: 5; doi:10.1093/annonc/7.suppl_1.5 [PDF] [Request Permissions]  

Background Information Back

M.W. Lobbezoo
NCI-EORTC Symposium on New Drugs in Cancer Therapy
Ann Oncol 1996 7: 6; doi:10.1093/annonc/7.suppl_1.6 [PDF] [Request Permissions]  

C.K. Kalken
The EORTC New Drug Development Office (NDDO)
Ann Oncol 1996 7: 7; doi:10.1093/annonc/7.suppl_1.7 [PDF] [Request Permissions]  

Acknowledgements Back

Committees
Ann Oncol 1996 7: 8; doi:10.1093/annonc/7.suppl_1.8-a [PDF] [Request Permissions]  

Financial support
Ann Oncol 1996 7: 8; doi:10.1093/annonc/7.suppl_1.8-b [PDF] [Request Permissions]  

Abstracts Back

Special workshop: 1. How can preclinical toxicology help the phase I clinical trial in oncology?
Ann Oncol 1996 7: 9; doi:10.1093/annonc/7.suppl_1.9 [PDF] [Request Permissions]  

Special workshop: 2. Clinical strategies for the evaluation of vaccines
Ann Oncol 1996 7: 10-11; doi:10.1093/annonc/7.suppl_1.10 [PDF] [Request Permissions]  

Special workshop: 3. Screening strategies in drug discovery
Ann Oncol 1996 7: 12; doi:10.1093/annonc/7.suppl_1.12 [PDF] [Request Permissions]  

Special workshop: 4. Phase I study design
Ann Oncol 1996 7: 13-14; doi:10.1093/annonc/7.suppl_1.13 [PDF] [Request Permissions]  

Opening ceremony: Second Michel Clavel lecture; Keynote lectures
Ann Oncol 1996 7: 15; doi:10.1093/annonc/7.suppl_1.15 [PDF] [Request Permissions]  

Lecture sessions: 1. Biological therapy of cancer
Ann Oncol 1996 7: 17; doi:10.1093/annonc/7.suppl_1.17 [PDF] [Request Permissions]  

Lecture sessions: 2. Immunotherapy with tumor vaccines
Ann Oncol 1996 7: 18; doi:10.1093/annonc/7.suppl_1.18 [PDF] [Request Permissions]  

Lecture sessions: 3. Preclinical drug research
Ann Oncol 1996 7: 19-20; doi:10.1093/annonc/7.suppl_1.19 [PDF] [Request Permissions]  

Lecture sessions: 4. Cell cycle control and apoptosis
Ann Oncol 1996 7: 21; doi:10.1093/annonc/7.suppl_1.21 [PDF] [Request Permissions]  

Lecture sessions: 5. New mechanisms and cellular targets for anticancer agents (part 1)
Ann Oncol 1996 7: 22; doi:10.1093/annonc/7.suppl_1.22 [PDF] [Request Permissions]  

Lecture sessions: 6. Gene therapy
Ann Oncol 1996 7: 23; doi:10.1093/annonc/7.suppl_1.23 [PDF] [Request Permissions]  

Lecture sessions: 7. Biodistribution of anticancer drugs
Ann Oncol 1996 7: 24; doi:10.1093/annonc/7.suppl_1.24 [PDF] [Request Permissions]  

Lecture sessions: 8. New drugs in clinical research (part 1)
Ann Oncol 1996 7: 25-26; doi:10.1093/annonc/7.suppl_1.25 [PDF] [Request Permissions]  

Lecture sessions: 9. New mechanisms and cell War targets for anticancer agents (part 2)
Ann Oncol 1996 7: 27-28; doi:10.1093/annonc/7.suppl_1.27 [PDF] [Request Permissions]  

Lecture sessions: 10. New drugs in clinical research (part 2)
Ann Oncol 1996 7: 29-30; doi:10.1093/annonc/7.suppl_1.29 [PDF] [Request Permissions]  

Poster sessions: 1. Drug screening models
Ann Oncol 1996 7: 31-32; doi:10.1093/annonc/7.suppl_1.31 [PDF] [Request Permissions]  

Poster sessions: 2. Preclinical screening of natural products (including marine compounds)
Ann Oncol 1996 7: 33-35; doi:10.1093/annonc/7.suppl_1.33 [PDF] [Request Permissions]  

Poster sessions: 3. Preclinical screening of platinum complexes
Ann Oncol 1996 7: 36-38; doi:10.1093/annonc/7.suppl_1.36 [PDF] [Request Permissions]  

Poster sessions: 4. Preclinical screening of bioreductive agents
Ann Oncol 1996 7: 39-40; doi:10.1093/annonc/7.suppl_1.39 [PDF] [Request Permissions]  

Poster sessions: 5. Preclinical screening of miscellaneous agents
Ann Oncol 1996 7: 41-46; doi:10.1093/annonc/7.suppl_1.41 [PDF] [Request Permissions]  

Poster sessions: 6. Formulation research and stability studies
Ann Oncol 1996 7: 47-48; doi:10.1093/annonc/7.suppl_1.47 [PDF] [Request Permissions]  

Poster sessions: 7. Preclinical pharmacokinetic studies and assay development
Ann Oncol 1996 7: 49-52; doi:10.1093/annonc/7.suppl_1.49 [PDF] [Request Permissions]  

Poster sessions: 8. Cytokines and immunomodulators - Preclinical and clinical studies
Ann Oncol 1996 7: 53-55; doi:10.1093/annonc/7.suppl_1.53 [PDF] [Request Permissions]  

Poster sessions: 9. Monoclonal antibodies and conjugates
Ann Oncol 1996 7: 56-57; doi:10.1093/annonc/7.suppl_1.56 [PDF] [Request Permissions]  

Poster sessions: 10. Cancer vaccines and gene therapy
Ann Oncol 1996 7: 58-59; doi:10.1093/annonc/7.suppl_1.58 [PDF] [Request Permissions]  

Poster sessions: 11. Haemopoietic growth factors
Ann Oncol 1996 7: 60-61; doi:10.1093/annonc/7.suppl_1.60 [PDF] [Request Permissions]  

Poster sessions: 12. Chemoprevention and differentiation inducers
Ann Oncol 1996 7: 62-64; doi:10.1093/annonc/7.suppl_1.62 [PDF] [Request Permissions]  

Poster sessions: 13. Antimetabolites - Preclinical and clinical studies (part 1)
Ann Oncol 1996 7: 65-70; doi:10.1093/annonc/7.suppl_1.65 [PDF] [Request Permissions]  

Poster sessions: 14. New mechanisms and targets - Telomerase
Ann Oncol 1996 7: 71; doi:10.1093/annonc/7.suppl_1.71 [PDF] [Request Permissions]  

Poster sessions: 15. New mechanisms and targets - Metastasis and angiogenesis
Ann Oncol 1996 7: 72-74; doi:10.1093/annonc/7.suppl_1.72 [PDF] [Request Permissions]  

Poster sessions: 16. New mechanisms and targets - Signal transduction
Ann Oncol 1996 7: 75-77; doi:10.1093/annonc/7.suppl_1.75 [PDF] [Request Permissions]  

Poster sessions: 17. Apoptosis
Ann Oncol 1996 7: 78-80; doi:10.1093/annonc/7.suppl_1.78 [PDF] [Request Permissions]  

Poster sessions: 18. Mechanism of action studies
Ann Oncol 1996 7: 81-84; doi:10.1093/annonc/7.suppl_1.81 [PDF] [Request Permissions]  

Poster sessions: 19. Antimetabolites - Preclinical and clinical studies (part 2)
Ann Oncol 1996 7: 85-90; doi:10.1093/annonc/7.suppl_1.85 [PDF] [Request Permissions]  

Poster sessions: 20. Taxoids - Preclinical and clinical studies
Ann Oncol 1996 7: 91-96; doi:10.1093/annonc/7.suppl_1.91 [PDF] [Request Permissions]  

Poster sessions: 21. Phase I and clinical pharmacokinetic studies
Ann Oncol 1996 7: 97-104; doi:10.1093/annonc/7.suppl_1.97 [PDF] [Request Permissions]  

Poster sessions: 22. Drug design, synthesis, acquisition and structure-activity relationships
Ann Oncol 1996 7: 105-113; doi:10.1093/annonc/7.suppl_1.105 [PDF] [Request Permissions]  

Poster sessions: 23. Preclinical toxicology and toxicity modulators - Preclinical studies
Ann Oncol 1996 7: 114-117; doi:10.1093/annonc/7.suppl_1.114 [PDF] [Request Permissions]  

Poster sessions: 24. Drug resistance and modifiers - Preclinical and clinical studies
Ann Oncol 1996 7: 118-125; doi:10.1093/annonc/7.suppl_1.118 [PDF] [Request Permissions]  

Poster sessions: 25. Topoisomerase I inhibitors - Preclinical and clinical studies
Ann Oncol 1996 7: 126-133; doi:10.1093/annonc/7.suppl_1.126 [PDF] [Request Permissions]  

Poster sessions: 26. Phase II, phase III and other clinical studies
Ann Oncol 1996 7: 134-141; doi:10.1093/annonc/7.suppl_1.134 [PDF] [Request Permissions]  

Subject Index Back

Subject index
Ann Oncol 1996 7: 143-162; doi:10.1093/annonc/7.suppl_1.143 [PDF] [Request Permissions]  

Authors Index Back

Authors index
Ann Oncol 1996 7: 163-175; doi:10.1093/annonc/7.suppl_1.163 [PDF] [Request Permissions]  

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.